Fennec Pharmaceuticals Inc. (TSX:FRX)

Market Cap	360.16M +39.2%
Revenue (ttm)	54.03M -21.4%
Net Income	-9.67M
EPS	-0.36
Shares Out	n/a
PE Ratio	n/a
Forward PE	24.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	957
Open	10.32
Previous Close	10.53
Day's Range	10.32 - 10.52
52-Week Range	7.02 - 13.83
Beta	0.77
RSI	47.30
Earnings Date	Mar 25, 2026

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 32
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: FRX

Financial Performance

In 2024, Fennec Pharmaceuticals's revenue was $47.54 million, an increase of 123.69% compared to the previous year's $21.25 million. Losses were -$436,000, -97.28% less than in 2023.

Financial numbers in USD